読み込み中
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
前日終値
$1.08
+$0.01 · +0.93%
日中の時刻はETです。市場データは遅延する場合があります。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
44
適正価値
センチメント
58
まちまち
リスク
72
高リスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日中レンジ
現在 $1.08
52週レンジ
現在 $1.08
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 50万 USD | 50万 USD |
| 粗利益 | — | — | — | 50万 USD | 50万 USD |
| 研究開発 | 778.07万 USD | 1163.94万 USD | 1128.77万 USD | 1173.37万 USD | 1061.93万 USD |
| 販売・一般管理 | 687万 USD | 749.3万 USD | 974.27万 USD | 1368.79万 USD | 1088.79万 USD |
| 営業費用 | 1465.07万 USD | 1913.24万 USD | 2103.04万 USD | 2542.16万 USD | 2150.72万 USD |
| 受取利息 | 15.57万 USD | 45.02万 USD | 72.58万 USD | 50.26万 USD | 1.81万 USD |
| 支払利息 | — | — | 19.71万 USD | 502.86万 USD | 56.99万 USD |
| 減価償却費と償却費 | 69.89万 USD | 71.81万 USD | 72万 USD | 73.16万 USD | 70.29万 USD |
| 営業利益 | −1465.07万 USD | −1913.24万 USD | −2103.04万 USD | −2492.16万 USD | −2100.72万 USD |
| 純利益 | −1449.5万 USD | −1862.02万 USD | −1951.5万 USD | −3589.82万 USD | −2076.93万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.00
上昇余地（825.93%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
